ES8307095A1 - Un procedimiento para la estabilizacion de una composicion farmaceutica de trihidrato de amoxicilina y de clavulanato depotasio. - Google Patents

Un procedimiento para la estabilizacion de una composicion farmaceutica de trihidrato de amoxicilina y de clavulanato depotasio.

Info

Publication number
ES8307095A1
ES8307095A1 ES505803A ES505803A ES8307095A1 ES 8307095 A1 ES8307095 A1 ES 8307095A1 ES 505803 A ES505803 A ES 505803A ES 505803 A ES505803 A ES 505803A ES 8307095 A1 ES8307095 A1 ES 8307095A1
Authority
ES
Spain
Prior art keywords
amoxycillin
desiccant
clavulanic acid
pharmaceutical formulation
equivalent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES505803A
Other languages
English (en)
Other versions
ES505803A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10516342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8307095(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Publication of ES505803A0 publication Critical patent/ES505803A0/es
Publication of ES8307095A1 publication Critical patent/ES8307095A1/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PROCEDIMIENTO PARA LA ESTABILIZACION DE COMPOSICIONES FARMACEUTICAS DE TRIHIDRATO DE AMOXICILINA Y CLAVULANO DE POTASIO. CONSISTE EN MEZCLAR UN DESECANTE COMESTIBLE, TAL COMO GEL DE SILICE O ALUMINIO-SILICATO CRISTALINO DE SODIO, POTASIO O CALCIO, CON TRIHIDRATO DE AMOXICILINA EQUIVALENTE A 20-1500 MG. DE AMOXICILINA Y CLAVULANATO DE POTASIO EQUIVALENTE A 20-500 MG. DE ACIDO CLAVULANICO, PULVERIZADOS AMBOS A PARTICULAS DE TAMAÑO ENTRE 400 Y 700 MICRAS; Y COMPRIMIR LOS COMPONENTES MEZCLADOS EN FORMA DE TABLETA; TODO ELLO EN AMBIENTE CON HUMEDAD RELATIVA INFERIOR AL 30% Y TEMPERATURAS ENTRE 10 C Y 30 C. ESTAS COMPOSICIONES TIENEN APLICACIONES FARMACOLOGICAS PARA EL TRATAMIENTO DE INFECCIONES ANTIBACTERIANAS.
ES505803A 1980-09-27 1981-09-25 Un procedimiento para la estabilizacion de una composicion farmaceutica de trihidrato de amoxicilina y de clavulanato depotasio. Expired ES8307095A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8031298 1980-09-27

Publications (2)

Publication Number Publication Date
ES505803A0 ES505803A0 (es) 1983-06-16
ES8307095A1 true ES8307095A1 (es) 1983-06-16

Family

ID=10516342

Family Applications (1)

Application Number Title Priority Date Filing Date
ES505803A Expired ES8307095A1 (es) 1980-09-27 1981-09-25 Un procedimiento para la estabilizacion de una composicion farmaceutica de trihidrato de amoxicilina y de clavulanato depotasio.

Country Status (15)

Country Link
US (1) US4537887A (es)
EP (1) EP0049061B1 (es)
JP (1) JPS5791921A (es)
AU (1) AU549321B2 (es)
CA (1) CA1187796A (es)
DE (1) DE3172028D1 (es)
ES (1) ES8307095A1 (es)
GB (1) GB2084016B (es)
GR (1) GR75049B (es)
HK (1) HK17386A (es)
IE (1) IE51597B1 (es)
MY (1) MY8600353A (es)
NZ (1) NZ198241A (es)
PT (1) PT73686A (es)
ZA (1) ZA816272B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0080862B1 (en) * 1981-12-02 1985-09-25 Beecham Group Plc Pharmaceutical formulation comprising beta-lactam antibiotics
JPS59104319A (ja) * 1982-12-06 1984-06-16 Chugai Pharmaceut Co Ltd 抗菌剤およびそのキツト
ES2061623T3 (es) * 1987-03-02 1994-12-16 Brocades Pharma Bv Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico.
US5211958A (en) * 1987-11-30 1993-05-18 Gist-Brocades, N.V. Pharmaceutical composition and process for its preparation
ES2060737T3 (es) * 1988-02-25 1994-12-01 Yamanouchi Europ Bv Procedimiento de preparacion de un granulado farmaceutico.
US5643902A (en) * 1990-04-26 1997-07-01 Pfizer Inc. Veterinary treatment
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
GB9413542D0 (en) * 1994-07-05 1994-08-24 Smithkline Beecham Plc Pharmaceutical formulations
ES2171192T3 (es) * 1994-08-05 2002-09-01 Smithkline Beecham Plc Recipiente para material sensible a la humedad y metodos correspondientes de desecacion y de reduccion de la descomposicion de productos farmaceuticos.
GB9416600D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
DZ1926A1 (fr) * 1994-09-03 2002-02-17 Smithkline Beckman P L C Formulations pharmaceutiques.
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
DZ2028A1 (fr) * 1995-05-03 2002-10-23 Smithkline Beecham Plc Médicaments destinés au traitement d'infections bactériennes en pédiatrie.
US20030109503A1 (en) * 1995-06-06 2003-06-12 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
CZ299595B6 (cs) * 1995-09-07 2008-09-17 Smithkline Beecham Plc Farmaceutický prípravek a lécivo pro empirickou lécbu infekcí
ITMI952354A1 (it) * 1995-11-16 1997-05-16 Smithkline Beecham Spa Composizione farmaceutica
US5801796A (en) * 1996-05-10 1998-09-01 International Business Machines Corporation Stacked parallax-free liquid crystal display cell
GB9617780D0 (en) * 1996-08-24 1996-10-02 Smithkline Beecham Plc Method of treatment
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
CN1194687C (zh) * 1997-02-14 2005-03-30 史密斯克莱恩比彻姆药物实验室 含有阿莫西林和克拉维酸盐的药物制剂
US6296871B1 (en) * 1998-04-12 2001-10-02 Ranbaxy Laboratories Limited Stable solid pharmaceutical compositions containing enalapril maleate
US6177421B1 (en) 1999-05-04 2001-01-23 Fuisz International Ltd. Amoxicillin and clavulanate composition
IE990159A1 (en) * 1999-02-26 2000-09-20 Fuisz Internat Ltd Storage Stable Amoxycillin and Clavulanate Suspension Composition.
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6294199B1 (en) * 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
EP2305251A3 (en) * 1999-08-16 2011-05-18 Revaax Pharmaceuticals LLC Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of sexual disorder
WO2002030392A2 (en) 2000-10-12 2002-04-18 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
KR100456833B1 (ko) * 2002-08-01 2004-11-10 주식회사 대웅 아목시실린 및 클라불라네이트를 함유하는 유핵정
EP1902708A1 (de) 2006-09-25 2008-03-26 Losan Pharma GmbH Wirkstoff enthaltende stabilisierte feste Arzneimittelformen und Verfahren zu ihrer Herstellung
US20100255099A1 (en) * 2007-10-26 2010-10-07 Rexahn Pharmaceuticals, Inc. Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders
JP2011500811A (ja) * 2007-10-26 2011-01-06 レクサン ファーマシューティカルズ インコーポレイテッド クラブラン酸の医薬品製剤
US9919007B2 (en) 2013-03-15 2018-03-20 Braintree Laboratories, Inc. Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE888444C (de) * 1951-11-10 1953-08-31 Benckiser Gmbh Joh A Verfahren zum Tablettieren von hygroskopischen Praeparaten
US3432593A (en) * 1963-09-18 1969-03-11 Key Pharm Inc Delayed and sustained release type pharmaceutical preparation
GB1209634A (en) * 1967-06-29 1970-10-21 Rit Rech Ind Therapeut Stabilized antibiotic compositions for animal feeding and process for preparing them
DE2512247A1 (de) * 1975-03-20 1976-10-14 Thomae Gmbh Dr K Gegen feuchtigkeit stabilisierte presslinge mit feuchtigkeitsempfindlichen inhaltsstoffen
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
JO984B1 (en) * 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
IL58461A0 (en) * 1978-10-27 1980-01-31 Beecham Group Ltd Intramammary compositions comprising a clavulanic acid salt
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions

Also Published As

Publication number Publication date
MY8600353A (en) 1986-12-31
JPH0155244B2 (es) 1989-11-22
EP0049061A1 (en) 1982-04-07
AU7568481A (en) 1982-04-08
AU549321B2 (en) 1986-01-23
ES505803A0 (es) 1983-06-16
JPS5791921A (en) 1982-06-08
US4537887A (en) 1985-08-27
IE812232L (en) 1982-03-27
HK17386A (en) 1986-03-21
GB2084016A (en) 1982-04-07
GB2084016B (en) 1985-04-17
ZA816272B (en) 1982-09-29
DE3172028D1 (en) 1985-10-03
EP0049061B1 (en) 1985-08-28
IE51597B1 (en) 1987-01-21
PT73686A (pt) 1981-10-01
CA1187796A (en) 1985-05-28
NZ198241A (en) 1983-12-16
GR75049B (es) 1984-07-12

Similar Documents

Publication Publication Date Title
ES8307095A1 (es) Un procedimiento para la estabilizacion de una composicion farmaceutica de trihidrato de amoxicilina y de clavulanato depotasio.
IE782019L (en) Pharmaceutical compositions
EP1243267A3 (en) Amoxycillin and clavulanate containing pharmaceutical formulation
IT1211484B (it) Forma farmaceutica di dosaggio per somministrazione orale con erogazione controllata di un ingrediente attivo
ES2170069T3 (es) 1-alfa-hidroxiprevitamina d para administracion oral.
IL91656A0 (en) Pharmaceutical composition containing a benzodiazepine derivative
GB8623557D0 (en) Therapeutic agents
GB1459675A (en) Method for the prevention of conception
ATE220321T1 (de) Feste flupirtin enthaltende orale darreichungsformen mit kontrollierter wirkstoffabgabe
EP0414772A4 (en) Method for treating acne
IE42950L (en) X-ray contrast preparations
AU1196988A (en) Process for preparing a retard product containing diltiazem for a single daily administration
EP0302714A3 (en) Pharmaceutical composition for treatment of bone-wasting diseases
GB1487334A (en) Pharmaceutical preparations comprising lisuride and/or physiologically tolerable salts thereof
CA2078869A1 (en) Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use
GB1457546A (en) Pharmaceutical preparations comprising cephalosporin derivatives
GB1202148A (en) Pharmaceutical compositions
MY101916A (en) Etoposide oral dosage form.
GB1464467A (en) Pharmaceutical composition for the treatment of coronary
JPS5551019A (en) Drug containing alllee or 133zz7*88dehydroo retine acid and manufacture thereof
ATE136778T1 (de) Oral anzuwendende arzneimittel dapiprazol enthaltend
GB1302266A (es)
GB950162A (en) Medicines for the treatment of hepatic disorders
NZ315632A (en) Process for preparing solid dosage forms of very low-dose drugs comprising admixing 1-3% by weight of carrier particles with a solution of drug in water
IE35419L (en) Pharmaceutical composition containing cyclobenzaprine